ReShape Total Cash From Operating Activities from 2010 to 2024
| RSLS Stock | USD 0.23 0.02 8.00% |
Total Cash From Operating Activities | First Reported 2007-12-31 | Previous Quarter -2.5 M | Current Value -2.5 M | Quarterly Volatility 1.9 M |
Check ReShape Lifesciences financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among ReShape Lifesciences' main balance sheet or income statement drivers, such as Interest Expense of 24.7 K, Other Operating Expenses of 26.5 M or Total Operating Expenses of 24.6 M, as well as many indicators such as Price To Sales Ratio of 0.16, Dividend Yield of 0.0 or PTB Ratio of 0.21. ReShape financial statements analysis is a perfect complement when working with ReShape Lifesciences Valuation or Volatility modules.
ReShape | Total Cash From Operating Activities |
Latest ReShape Lifesciences' Total Cash From Operating Activities Growth Pattern
Below is the plot of the Total Cash From Operating Activities of ReShape Lifesciences over the last few years. It is ReShape Lifesciences' Total Cash From Operating Activities historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in ReShape Lifesciences' overall financial position and show how it may be relating to other accounts over time.
| Total Cash From Operating Activities | 10 Years Trend |
|
Total Cash From Operating Activities |
| Timeline |
ReShape Total Cash From Operating Activities Regression Statistics
| Arithmetic Mean | (18,709,166) | |
| Coefficient Of Variation | (27.36) | |
| Mean Deviation | 3,915,646 | |
| Median | (19,383,663) | |
| Standard Deviation | 5,117,927 | |
| Sample Variance | 26.2T | |
| Range | 18.9M | |
| R-Value | 0.07 | |
| Mean Square Error | 28.1T | |
| R-Squared | 0.01 | |
| Significance | 0.80 | |
| Slope | 81,113 | |
| Total Sum of Squares | 366.7T |
ReShape Total Cash From Operating Activities History
About ReShape Lifesciences Financial Statements
There are typically three primary documents that fall into the category of financial statements. These documents include ReShape Lifesciences income statement, its balance sheet, and the statement of cash flows. ReShape Lifesciences investors use historical funamental indicators, such as ReShape Lifesciences's Total Cash From Operating Activities, to determine how well the company is positioned to perform in the future. Although ReShape Lifesciences investors may use each financial statement separately, they are all related. The changes in ReShape Lifesciences's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on ReShape Lifesciences's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on ReShape Lifesciences Financial Statements. Understanding these patterns can help to make the right decision on long term investment in ReShape Lifesciences. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Total Cash From Operating Activities | -17 M | -17.8 M |
Pair Trading with ReShape Lifesciences
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if ReShape Lifesciences position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in ReShape Lifesciences will appreciate offsetting losses from the drop in the long position's value.Moving together with ReShape Stock
| 0.65 | DH | Definitive Healthcare | PairCorr |
| 0.86 | DYNT | Dynatronics Fiscal Year End 26th of September 2024 | PairCorr |
Moving against ReShape Stock
| 0.72 | AHG | Akso Health Group | PairCorr |
| 0.72 | CAH | Cardinal Health Fiscal Year End 20th of August 2024 | PairCorr |
| 0.56 | FEMY | Femasys | PairCorr |
| 0.48 | XTNT | Xtant Medical Holdings | PairCorr |
| 0.41 | FORA | Forian Inc | PairCorr |
The ability to find closely correlated positions to ReShape Lifesciences could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace ReShape Lifesciences when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back ReShape Lifesciences - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling ReShape Lifesciences to buy it.
The correlation of ReShape Lifesciences is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as ReShape Lifesciences moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if ReShape Lifesciences moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for ReShape Lifesciences can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Additional Tools for ReShape Stock Analysis
When running ReShape Lifesciences' price analysis, check to measure ReShape Lifesciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ReShape Lifesciences is operating at the current time. Most of ReShape Lifesciences' value examination focuses on studying past and present price action to predict the probability of ReShape Lifesciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ReShape Lifesciences' price. Additionally, you may evaluate how the addition of ReShape Lifesciences to your portfolios can decrease your overall portfolio volatility.